Related Experiment Videos
Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models
1Molecular Urology and Therapeutics Program, Department of Urology, University of Virginia Health Sciences Center, Charlottesville 22908, USA.
Abstract:
Osteocalcin (OC), a noncollagenous bone matrix protein, is expressed in high levels by osteoblasts. To determine whether the OC promoter mediates cell-specific gene expression in cells of osteoblast lineage, we constructed a recombinant adenovirus, Ad-OC-TK, which contains the OC promoter that drives the expression of herpes simplex virus thymidine kinase (TK). We tested the expression of TK by this virus in osteoblast cell lines as well as in non-osteoblastic cell lines by assessing the enzyme activity of TK in vitro. Whereas the OC promoter failed to drive the expression of the TK gene in several non-osteoblastic cell lines such as WH, a human bladder transitional carcinoma, and NIH 3T3, an embryonic mouse fibroblast cell line, the OC promoter mediated high levels of expression in osteoblast cell lines including murine ROS and human MG-63 cells. The addition of acyclovir (ACV), a pro-drug for the inhibition of cell proliferation, resulted in the induction of osteoblast-specific cell death in vitro. Intratumoral injection of Ad-OC-TK into murine ROS osteosarcoma abolished tumor growth in a host treated with subsequent i.p. ACV injection in vivo. The Ad-OC-TK virus plus ACV treatment appears to be highly selective in blocking the growth of both murine and human osteosarcoma cell lines in vitro and murine osteosarcoma in vivo.
Insights
Osteocalcin promoter drives gene expression specifically in osteoblasts. This allows targeted cancer therapy, leading to osteosarcoma cell death both in vitro and in vivo.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Osteocalcin (OC) is a bone matrix protein primarily produced by osteoblasts.
- Targeting osteoblast-specific gene expression is crucial for developing selective therapies.
Purpose of the Study:
- To investigate if the osteocalcin promoter can mediate cell-specific gene expression in osteoblast lineage cells.
- To evaluate the potential of a recombinant adenovirus carrying the OC promoter and herpes simplex virus thymidine kinase (TK) for targeted cancer therapy.
Main Methods:
- Construction of a recombinant adenovirus (Ad-OC-TK) with the OC promoter driving TK expression.
- Testing TK expression in various osteoblast and non-osteoblastic cell lines in vitro.
- Assessing the effect of Ad-OC-TK and acyclovir (ACV) on osteosarcoma cell growth in vitro and in vivo.
Main Results:
- The OC promoter demonstrated high-level, cell-specific gene expression in osteoblast cell lines (murine ROS, human MG-63).
- The promoter failed to drive expression in non-osteoblastic cell lines (WH, NIH 3T3).
- Ad-OC-TK combined with ACV induced osteoblast-specific cell death in vitro and abolished tumor growth in vivo.
Conclusions:
- The osteocalcin promoter is effective in mediating osteoblast-specific gene expression.
- Ad-OC-TK and ACV offer a highly selective therapeutic strategy against osteosarcoma, minimizing off-target effects.